Drug class profile · refreshed daily from federal data

Quinolone Antimicrobial

9 molecules in this class, $50.3M combined CY2024 Part D spend across 2.3M claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.

Last updated 14 Jul 2026

NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annualOrange Book: weeklyShortages: daily

Class summary at a glance.

Every drug in the Quinolone Antimicrobial class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 9tracked in Part D
CY24 Part D spend: $50.3Mcombined across class
Total Rx claims: 2.3M1.7M unique beneficiaries
Generic mfrs (active): 16across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Ofloxacin

Brand: OCUFLOX · 2.2M Part D claims (CY24) · 1.7M beneficiaries · First FDA approval: 1993-08-01

14 generic mfrs 0 plans require PA

Low NADAC$0.952

→

Avg plan cost$1.15

Part D spend $39.4M 1× spread, current vs floor

Class share

78%

of class CY24 spend

View profile →

Besifloxacin

Brand: Besivance · 40K Part D claims (CY24) · 27K beneficiaries · First FDA approval: 2009-05-28

Brand-only (no generics) 1 plans require PA

Low NADAC$44.09

→

Avg plan cost$44.09

Part D spend $9.0M 1× spread, current vs floor

Class share

18%

of class CY24 spend

View profile →

Gatifloxacin

Brand: ZYMAXID · 43K Part D claims (CY24) · 29K beneficiaries · First FDA approval: 2010-05-19

2 generic mfrs 0 plans require PA

Low NADAC$7.99

→

Avg plan cost$7.99

Part D spend $2.0M 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Gatifloxacin Ophthalmic Solution

— Part D claims (CY24) · First FDA approval: 2025-10-06

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Ofloxacin Ophth Soln

— Part D claims (CY24) · First FDA approval: 2023-05-22

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Ofloxacin Ophthalmic Solution Usp,

Brand: Ofloxacin · — Part D claims (CY24) · First FDA approval: 2024-04-30

Brand-only (no generics)

Low NADAC$1.13

→

Avg plan cost$1.22

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Ofloxacin Otic

Brand: Ofloxacin · — Part D claims (CY24) · First FDA approval: 2019-08-30

Brand-only (no generics) 0 plans require PA

Low NADAC$0.952

→

Avg plan cost$1.05

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Ofloxacin Otic Solution

Brand: Ofloxacin · — Part D claims (CY24) · First FDA approval: 2024-12-16

Brand-only (no generics)

Low NADAC$0.952

→

Avg plan cost$0.952

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Olfoxacin Otic Soln

— Part D claims (CY24) · First FDA approval: 2023-06-08

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.